sTREM2 is a plasma biomarker for human NASH and promotes hepatocyte lipid accumulation.
Vishal KothariChristopher SavardJingjing TangSum P LeeSavitha SubramanianShari WangLaura J den HartighKarin E BornfeldtGeorge N IoannouPublished in: Hepatology communications (2023)
Elevated levels of sTREM2 due to TREM2 shedding may directly contribute to the pathogenesis of NAFLD by promoting hepatocyte lipid accumulation, as well as serving as a biomarker for distinguishing patients with NASH versus NAFL. Further investigation of sTREM2 as a clinically useful diagnostic biomarker and of the therapeutic effects of targeting sTREM2 in NASH is warranted.
Keyphrases